MedStar Georgetown University Hospital, Washington, DC, USA Washington, DC
Bisher Sawaf, MD1, Shahem Abbarh, MD2, Yusuf Omar Hallak, MD3, Munir Abu Ageila, MD4, Yzen Al-Marrawi, BS5, Hayder Alamily, MD6, Mulham Alom, MD7, Tarek Abou Rashid, MD8, Elias Battikh, MD9, Amine Rakab, MD10, Kaled Ejji, MD4 1University of Toledo Medical Center, Toledo, OH; 2Georgetown University MedStar Health, Baltimore, WA; 3The University of Toledo, Toledo, OH; 4Hamad Medical Corporation, Doha, Ad Dawhah, Qatar; 5Oakland University William Beaumont School of Medicine, Detroit, MI; 6University of Colorado Anschutz Medical Campus, Denver, CO; 7Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL; 8MedStar Georgetown University Hospital, Washington, DC, USA, Washington, DC; 9John H. Stroger, Jr. Hospital of Cook County, Toledo, OH; 10Division of Medical Education, Weill Cornell Medicine, Doha, Ad Dawhah, Qatar Introduction: Tumor necrosis factor-alpha (TNFα) inhibitors, including adalimumab, are widely used to manage autoimmune conditions like Crohn's disease. Although these agents generally have a favorable safety profile, emerging evidence links TNFα inhibitors to psychiatric side effects, particularly mood disturbances.
Case Description/
Methods: We present a case of a 19-year-old woman with Crohn's disease and no prior psychiatric history who developed a new-onset manic episode after starting adalimumab. The patient had no prior psychiatric history and exhibited agitation, hyperactivity, and religious preoccupation shortly after receiving two doses of adalimumab. Following discontinuation of the medication and psychiatric treatment, her symptoms resolved, and she remained stable for a year. Discussion: This case adds to the growing body of literature suggesting a potential link between TNFα inhibitors and manic episodes, highlighting the need for awareness and further research into their psychiatric effects.
Disclosures: Bisher Sawaf indicated no relevant financial relationships. Shahem Abbarh indicated no relevant financial relationships. Yusuf Omar Hallak indicated no relevant financial relationships. Munir Abu Ageila indicated no relevant financial relationships. Yzen Al-Marrawi indicated no relevant financial relationships. Hayder Alamily indicated no relevant financial relationships. Mulham Alom indicated no relevant financial relationships. Tarek Abou Rashid indicated no relevant financial relationships. Elias Battikh indicated no relevant financial relationships. Amine Rakab indicated no relevant financial relationships. Kaled Ejji indicated no relevant financial relationships.
Bisher Sawaf, MD1, Shahem Abbarh, MD2, Yusuf Omar Hallak, MD3, Munir Abu Ageila, MD4, Yzen Al-Marrawi, BS5, Hayder Alamily, MD6, Mulham Alom, MD7, Tarek Abou Rashid, MD8, Elias Battikh, MD9, Amine Rakab, MD10, Kaled Ejji, MD4. P3354 - Adalimumab-Induced Mania in a Crohn's Disease Patient: A Case Report, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.
